Moneycontrol PRO
Open App
you are here: HomeNewsBusiness

Alembic Pharma gets USFDA nod for blood pressure drug

The company has received final approval from the US Food and Drug Administration (USFDA) to market the product in the US in strengths of 25 mg and 50 mg, the drug maker said in a statement.

August 29, 2022 / 02:25 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Alembic Pharmaceuticals on Monday said it has received an approval from the US health regulator for chlorthalidone tablets, used in treating high blood pressure.

The company has received final approval from the US Food and Drug Administration (USFDA) to market the product in the US in strengths of 25 mg and 50 mg, the drug maker said in a statement.

Alembic's product is therapeutically equivalent to Sanofi Aventis' Hygroton tablets. Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.

Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.

The product has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.

Close
According to IQVIA, chlorthalidone tablets had an estimated market size of USD 37 million for 12 months ended June 2022.
PTI
first published: Aug 29, 2022 02:28 pm
Sections
ISO 27001 - BSI Assurance Mark